4-bromo-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid | 958879-04-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-bromo-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid
• 英文别名: 4-bromo-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)pyrazole-3-carboxylic acid
• CAS: 958879-04-4
• 化学式: C₁₆H₈BrCl₃N₂O₂
• 分子量: 446.515
• InChiKey: YNJJZXXBIANKFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-bromo-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Synthesis, Structure−Activity Relationship, and Evaluation of SR141716 Analogues:  Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity

  摘要：

  Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophilic compounds that exhibit very high nonspecific to specific binding ratios and as a result are inapt for use in humans. We have synthesized a series of less lipophilic analogues of SR141716 to serve as potential radioligands. Binding affinities of the series and a functional electrophysiological assay of three of our compounds have been presented.

  DOI：

  10.1021/jm020157x
• 作为产物：
  描述：

  2,4-二氯苯肼盐酸盐 在 氢氧化钾 、 溴 、 lithium hexamethyldisilazane 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 生成 4-bromo-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxylic acid
  参考文献：
  名称：

  Synthesis, Structure−Activity Relationship, and Evaluation of SR141716 Analogues:  Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity

  摘要：

  Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophilic compounds that exhibit very high nonspecific to specific binding ratios and as a result are inapt for use in humans. We have synthesized a series of less lipophilic analogues of SR141716 to serve as potential radioligands. Binding affinities of the series and a functional electrophysiological assay of three of our compounds have been presented.

  DOI：

  10.1021/jm020157x

文献信息

• Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists
  申请人：LEE Jinhwa

  公开号：US20080081812A1

  公开（公告）日：2008-04-03

  A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB 1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

  一种异芳基-吡唑化合物，其公式为(I)或其药用可接受盐，可作为大麻素CB1受体的反向激动剂或拮抗剂，用于预防或治疗肥胖及其相关代谢紊乱。本发明还提供了制备本发明的异芳基-吡唑化合物或其药用可接受盐的方法，包含该化合物的药物组合物，以及用于预防或治疗肥胖及其相关代谢紊乱的方法。
• SULPHUR CONTAINING PYRAZOLE DERIVATIVES AS SELECTIVE CANNABINOID CB1 RECEPTOR ANTAGONISTS
  申请人：Lange Josephus H.M.

  公开号：US20070281973A1

  公开（公告）日：2007-12-06

  The present invention relates to sulphur containing pyrazole derivatives, and their S-oxidized active metabolites, as selective cannabinoid CB 1 receptor antagonists having a high CB 1 /CB 2 receptor subtype selectivity, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of these pyrazole derivatives, to pharmaceutical compositions comprising one or more of these pyrazole derivatives as active ingredients, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

  本发明涉及含硫吡唑衍生物及其S-氧化活性代谢物，作为具有高CB1/CB2受体亚型选择性的选择性大麻素CB1受体拮抗剂，以及制备这些化合物的方法，用于合成这些吡唑衍生物的新型中间体，包含一种或多种这些吡唑衍生物作为活性成分的药物组合物，以及这些药物组合物用于治疗精神疾病和神经疾病的用途。这些化合物具有通式（I），其中符号的含义如规范中所述。
• Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
  申请人：Green Cross Corporation

  公开号：US07875647B2

  公开（公告）日：2011-01-25

  A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.

  式(I)的杂环吡唑化合物或其药学上可接受的盐，是一种有效的大麻素CB1受体反向激动剂或拮抗剂，可用于预防或治疗肥胖和肥胖相关代谢障碍。本发明还提供了一种制备上述杂环吡唑化合物或其药学上可接受的盐的方法，以及包含它们的制药组合物和预防或治疗肥胖和肥胖相关代谢障碍的方法。
• Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
  申请人：Solvay Pharmaceuticals B.V.

  公开号：US07786144B2

  公开（公告）日：2010-08-31

  The present invention relates to sulphur containing pyrazole derivatives, and their S-oxidized active metabolites, as selective cannabinoid CB1 receptor antagonists having a high CB1/CB2 receptor subtype selectivity, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of these pyrazole derivatives, to pharmaceutical compositions comprising one or more of these pyrazole derivatives as active ingredients, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

  本发明涉及含硫的吡唑衍生物及其S-氧化活性代谢物，作为具有高CB1/CB2受体亚型选择性的选择性大麻素CB1受体拮抗剂，以及制备这些化合物的方法，用于合成这些吡唑衍生物的新型中间体，包含一种或多种这些吡唑衍生物作为活性成分的制药组合物，以及利用这些制药组合物治疗精神和神经系统疾病的用途。这些化合物的一般式为（I），其中符号的含义在规范中给出。
• Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
  申请人：Lange Josephus H. M.

  公开号：US08461184B2

  公开（公告）日：2013-06-11

  The present invention relates to sulphur containing pyrazole derivatives, and their S-oxidized active metabolites, as selective cannabinoid CB1 receptor antagonists having a high CB1/CB2 receptor subtype selectivity, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of these pyrazole derivatives, to pharmaceutical compositions comprising one or more of these pyrazole derivatives as active ingredients, as well as to the use of these pharmaceutical compositions for the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

  本发明涉及含硫吡唑衍生物及其S-氧化的活性代谢物，作为高CB1/CB2受体亚型选择性的选择性大麻素CB1受体拮抗剂，以及制备这些化合物的方法，用于合成这些吡唑衍生物的新型中间体，包含一种或多种这些吡唑衍生物作为活性成分的制药组合物，以及将这些制药组合物用于治疗精神和神经疾病的用途。这些化合物具有通式(I)，其中符号在规范中给出。